Open access journal of the Ferrata-Storti Foundation, a non-profit organization
Letters to the Editor

Ixazomib, pomalidomide and dexamethasone in relapsed or refractory multiple myeloma characterized with high-risk cytogenetics: the IFM 2014-01 study

University, U1313, U1402, Poitiers
Department of Hematology, University hospital and INSERM UMR-S1277, Lille
Clinical investigation center CIC INSERM 1402, University hospital, Poitiers
Takeda Development Center Americas, Cambridge MA
Department of Hematology, Haut-Lévêque hospital, Pessac
Department of clinical Hematology, Civils Hospices, Lyon
Department of Oncology Hematology, Bourgogne Cancerology Institute, Dijon
Department of Oncology Hematology, Bourgogne Cancerology Institute, Dijon
Department of Hematology, University hospital, Grenoble
Department of Hematology, Côte basque hospital, Bayonne
Department of Hematology, Saint-Louis hospital, Paris
Department of Hematology, private hospital, Cesson-Sévigné
Lymphoid hemopathies Unit, Henri Mondor University hospital, Créteil
Department of Hematology and cell therapy, Tours University hospital
Department of clinical Hematology, Avicenne hospital, Bobigny
Department of Onco-Hematology, hospital, Périgueux
Department of Clinical Hematology, UMR U1236 INSERM, University, Rennes
Blood disease department, University hospital, Angers
Department of Hematology, hospital, Dunkerque
Department of Hematology, University hospital - Brabois hospitals, Vandoeuvre les Nancy
Department of Hematology, ICANS University hospital, Strasbourg
Department of clinical Hematology, University hospital, Robert Debré Hospital, Reims
Department of clinical Hematology and cell therapy, University hospital, Limoges
Department of Hematology, Henri Becquerel center, Rouen
Department of clinical Hematology, University hospital, Caen
Department of clinical Hematology, Archet hospital, Nice
Department of Onco-Hematology, Vendée departmental hospital, La Roche/Yon
Department of clinical Hematology, University, Montpellier
Department of Onco-Hematology, Henri Duffaut hospital, Avignon
Intergroupe Francophone du Myélome, Paris
Intergroupe Francophone du Myélome, Paris
University, U1313, U1402, Poitiers
University, U1313, U1402, Poitiers
Department of Onco-Hematology, hospital, Vichy
Department of clinical Hematology, University hospital, Hôtel Dieu, Nantes
Department of Hematology, CRCT INSERM 1037, University hospital, IUCT-O, Toulouse
Department of clinical Hematology, University hospital, Hôtel Dieu, Nantes
Department of Hematology, University hospital and INSERM UMR-S1277, Lille
Unit for Genomics in Myeloma, CRCT INSERM 1037, University hospital, IUCT-O, Toulouse
Clinical investigation center CIC INSERM 1402, University hospital, Poitiers
Unit for Genomics in Myeloma, CRCT INSERM 1037, University hospital, IUCT-O, Toulouse
University, U1313, U1402, Poitiers
Haematologica Early view Nov 14, 2024 https://doi.org/10.3324/haematol.2024.285916

Abstract

Not available.

Figures & Tables

Article Information

Early view : Letters to the Editor
 
DOI
https://doi.org/10.3324/haematol.2024.285916
 
Published
2024-11-14
Published By
Ferrata Storti Foundation, Pavia, Italy
Print ISSN
0390-6078
Online ISSN
1592-8721
 
Copyright & Usage
Copyright (c) 2024 Ferrata Storti Foundation
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Article Usage

Online Views
45
PDF Downloads
26

Statistics from Altmetric.com

No Data
Navigate
For Authors
For Reviewers
For Advertisers
Education
Privacy
More
Copyright © 2024 by the Ferrata Storti Foundation | Web design ￫ | Development ￫
ISSN 0390-6078 print | ISSN 1592-8721 online